Alaunos Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Holger Weis
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 501 E. Las Olas Blvd. Fort Lauderdale FL United States of America 33301
- IPO Date
- Aug 24, 2005
- CIK
- 0001107421
- Website
- alaunos.com
- Similar Companies
- Business
- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) is a clinical-stage biotechnology company focused on developing cell therapies for oncology and preclinical small molecule therapeutics for obesity and metabolic disorders. The company engineers adoptive T-cell receptor (TCR) T-cell therapies, or TCR-T, utilizing its proprietary non-viral Sleeping Beauty gene transfer platform and a TCR library targeting neoantigens from hotspot mutations in genes such as KRAS, TP53, and EGFR; these therapies address solid tumors including colorectal, pancreatic, lung, and ovarian cancers through patient-specific autologous cell products that express tumor-specific TCRs and cytokines like mbIL-15. It also advances an internal oral small molecule obesity program featuring compounds such as ALN1001 and derivatives designed to promote weight loss while preserving lean muscle mass, differentiating from injectable GLP-1 receptor agonists by targeting lipid deposition and gene expression. Founded in 2003 and headquartered in Houston, Texas, Alaunos Therapeutics operates primarily in the United States with clinical collaborations including a Phase 1/2 trial at The University of Texas MD Anderson Cancer Center evaluating TCRs against mutated KRAS in various solid tumors. The company serves patients with unmet needs in oncology and metabolic diseases through its discovery engine, which supports expansion of the TCR library, and rapid manufacturing processes for TCR-T products. In recent developments, Alaunos Therapeutics terminated a key licensing agreement in 2024, enabling a strategic pivot with cost reductions that extended its cash runway into the first quarter of 2025; it initiated in vitro testing of small molecule obesity candidates in the fourth quarter of 2024, with in vivo studies planned for the first half of 2025 pending additional funding or partnerships. Early 2025 data from its TCR-T Library Phase 1/2 trial reported the first objective clinical response in solid tumors, while investor PMGC Capital urged acceptance of a non-toxic strategic financing term sheet in June 2025 to enhance shareholder value. The company filed a $50 million mixed shelf offering in August 2025 and reported Q2 2025 earnings, reflecting ongoing operational adjustments amid no revenue generation.
Company News
Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday?
Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics
Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules
Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies
Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models
Valion Bio Appoints Melinda Lackey as General Counsel
Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop
Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders
Short Interest in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Drops By 14.6%
Alaunos Therapeutics (NASDAQ:TCRT) Trading 3.1% Higher – What’s Next?
Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering
PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies
PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
Why Is Alaunos Therapeutics (TCRT) Stock Up 14% Today?
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%
Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives